tenecteplase

DrugBank

parenteral route of administration

17 November 2015

C₂₅₆₁H₃₉₁₉N₇₄₇O₇₈₁S₄₀

0 references

defined daily dose

40 milligram

route of administration

1 reference

https://www.whocc.no/atc_ddd_index/?code=B01AD11

active ingredient in

Metalyse

1 reference

European Medicines Agency product number

EMEA/H/C/000306

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000306/human_med_000900.jsp

Tenecteplase Boehringer Ingelheim Pharma Gmbh & Co. Kg

22 March 2017

1 reference

European Medicines Agency product number

EMEA/H/C/000307

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000307/human_med_001086.jsp

medical condition treated

22 March 2017

myocardial infarction

1 reference

13 December 2016

1 reference

acute myocardial infarction

13 December 2016

1 reference

Drug Indications Extracted from FAERS

significant drug interaction

2 October 2018

enoxaparin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dalteparin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tinzaparin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

rac-warfarin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fondaparinux

1 reference

A reference set of clinically relevant adverse drug-drug interactions

heparin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

acenocoumarol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

phenindione

1 reference

A reference set of clinically relevant adverse drug-drug interactions

rivaroxaban

1 reference

A reference set of clinically relevant adverse drug-drug interactions

apixaban

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ticagrelor

1 reference

A reference set of clinically relevant adverse drug-drug interactions

aspirin

1 reference

probably

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

1 reference

Open Targets Platform

14 August 2023

https://platform.opentargets.org/drug/CHEMBL2108791

route of administration

intravenous infusion and defusion

0 references

has characteristic

biopharmaceutical

1 reference

Tenecteplase (English)

DrugBank

17 November 2015

1 reference

Medical Subject Headings

MeSH descriptor ID

C121182

15 March 2018

Identifiers

1 reference

Tenecteplase (English)

17 November 2015

1 reference

Tenecteplase (English)

19 January 2016

1 reference

Tenecteplase (English)

17 November 2015

Tenecteplase

1 reference

D08.811.277.656.300.760.875.500

Medical Subject Headings

14 March 2018

0 references

D08.811.277.656.959.350.875.500

0 references

D12.776.124.125.662.768.500

0 references

1 reference

26 February 2018

0 references

1 reference

TENECTEPLASE (English)

19 January 2016

1 reference

TENECTEPLASE (English)

19 January 2016

1 reference